{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:55:08Z","timestamp":1792086908388,"version":"4.4.0"},"reference-count":64,"publisher":"American Society of Hematology","issue":"15","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,8,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Constitutive activation of the JAK\/STAT pathway is a common phenomenon in classic Hodgkin lymphoma (cHL). The clinical potential of anti-JAK\/STAT therapy is being explored in early-stage clinical trials. Notwithstanding, very little information is available about the complex biological consequences of this blockade. Here, we investigated the effects of JAK\/STAT pharmacological inhibition on cHL cell models using ruxolitinib, a JAK 1\/2 inhibitor that induces apoptosis by concentration- and time-dependent mechanisms. An unbiased whole-transcriptome approach identified expression of the anti-GCSF receptor (CSF3R) as a potential surrogate biomarker of JAK\/STAT overactivation. In addition, longitudinal gene expression analyses provided further mechanistic information about pertinent biological pathways involved, including 37 gene pathways distributed in 3 main clusters: cluster 1 was characterized by upregulation of the G2\/M checkpoint and major histocompatibility complex-related clusters; 2 additional clusters (2 and 3) showed a progressive downregulation of the tumor-promoting inflammation signatures: JAK\/STAT and interleukin 1 (IL-1)\/IL-4\/IL-13\/IL-17. Together, our results confirm the therapeutic potential of JAK\/STAT inhibitors in cHL, identify CSF3R as a new biomarker, and provide supporting genetic data and mechanistic understanding.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021006336","type":"journal-article","created":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T12:57:37Z","timestamp":1669985857000},"page":"4135-4147","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":10,"title":["JAK\/STAT blockade reverses the malignant phenotype of Hodgkin and Reed-Sternberg cells"],"prefix":"10.1182","volume":"7","author":[{"given":"Sara","family":"Fern\u00e1ndez","sequence":"first","affiliation":[{"name":"1Translational Research Laboratory, MD Anderson Cancer Center Madrid, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose L.","family":"Sol\u00f3rzano","sequence":"additional","affiliation":[{"name":"2Department of Pathology, MD Anderson Cancer Center Madrid, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"D\u00edaz","sequence":"additional","affiliation":[{"name":"1Translational Research Laboratory, MD Anderson Cancer Center Madrid, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Men\u00e9ndez","sequence":"additional","affiliation":[{"name":"1Translational Research Laboratory, MD Anderson Cancer Center Madrid, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Maestre","sequence":"additional","affiliation":[{"name":"3Monoclonal Antibodies Unit, Biotechnology Program, Spanish National Cancer Centre, Madrid, Spain"},{"name":"7Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Palacios","sequence":"additional","affiliation":[{"name":"1Translational Research Laboratory, MD Anderson Cancer Center Madrid, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar","family":"L\u00f3pez","sequence":"additional","affiliation":[{"name":"1Translational Research Laboratory, MD Anderson Cancer Center Madrid, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Argentina","family":"Colmenero","sequence":"additional","affiliation":[{"name":"4Flow Cytometry Unit, Eurofins-Megalab, MD Anderson Cancer Center Madrid, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f3nica","family":"Est\u00e9vez","sequence":"additional","affiliation":[{"name":"5Department of Hematology, MD Anderson Cancer Center Madrid, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Montalb\u00e1n","sequence":"additional","affiliation":[{"name":"5Department of Hematology, MD Anderson Cancer Center Madrid, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngel","family":"Mart\u00ednez","sequence":"additional","affiliation":[{"name":"6Cytogenetic Unit, Eurofins-Megalab, MD Anderson Cancer Center Madrid, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Roncador","sequence":"additional","affiliation":[{"name":"3Monoclonal Antibodies Unit, Biotechnology Program, Spanish National Cancer Centre, Madrid, Spain"},{"name":"7Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6974-0806","authenticated-orcid":false,"given":"Juan F.","family":"Garc\u00eda","sequence":"additional","affiliation":[{"name":"1Translational Research Laboratory, MD Anderson Cancer Center Madrid, Madrid, Spain"},{"name":"2Department of Pathology, MD Anderson Cancer Center Madrid, Madrid, Spain"},{"name":"7Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,8,1]]},"reference":[{"issue":"4","key":"2023080717055119300_bib1","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1182\/blood.V95.4.1443.004k55_1443_1450","article-title":"Hodgkin and Reed-Sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription","volume":"95","author":"Marafioti","year":"2000","journal-title":"Blood"},{"issue":"8","key":"2023080717055119300_bib2","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1182\/blood.V92.8.2899","article-title":"Detection of clonal Hodgkin and Reed-Sternberg cells with identical somatically mutated and rearranged VH genes in different biopsies in relapsed Hodgkin\u2019s disease","volume":"92","author":"Vockerodt","year":"1998","journal-title":"Blood"},{"issue":"7","key":"2023080717055119300_bib3","doi-asserted-by":"crossref","first-page":"794","DOI":"10.3324\/haematol.2015.132761","article-title":"The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints","volume":"101","author":"Vardhana","year":"2016","journal-title":"Haematologica"},{"issue":"4","key":"2023080717055119300_bib4","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/s41375-021-01204-6","article-title":"Molecular biology of Hodgkin lymphoma","volume":"35","author":"Weniger","year":"2021","journal-title":"Leukemia"},{"issue":"1","key":"2023080717055119300_bib5","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.canlet.2015.10.007","article-title":"Microenvironmental interactions in classical Hodgkin lymphoma and their role in promoting tumor growth, immune escape and drug resistance","volume":"380","author":"Aldinucci","year":"2016","journal-title":"Cancer Lett"},{"issue":"2","key":"2023080717055119300_bib6","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.cancergencyto.2009.11.005","article-title":"Mutations of NFKBIA in biopsy specimens from Hodgkin lymphoma","volume":"197","author":"Liu","year":"2010","journal-title":"Cancer Genet Cytogenet"},{"issue":"3","key":"2023080717055119300_bib7","first-page":"549","article-title":"Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells","volume":"60","author":"Joos","year":"2000","journal-title":"Cancer Res"},{"issue":"17","key":"2023080717055119300_bib8","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"issue":"3","key":"2023080717055119300_bib9","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41408-019-0195-7","article-title":"Genomic analyses of microdissected Hodgkin and Reed-Sternberg cells: mutations in epigenetic regulators and p53 are frequent in refractory classic Hodgkin lymphoma","volume":"9","author":"Mata","year":"2019","journal-title":"Blood Cancer J"},{"issue":"67","key":"2023080717055119300_bib10","doi-asserted-by":"crossref","first-page":"111386","DOI":"10.18632\/oncotarget.22799","article-title":"Analysis of the mutational landscape of classic Hodgkin lymphoma identifies disease heterogeneity and potential therapeutic targets","volume":"8","author":"Mata","year":"2017","journal-title":"Oncotarget"},{"issue":"22","key":"2023080717055119300_bib11","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2017-11-814913","article-title":"Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma","volume":"131","author":"Tiacci","year":"2018","journal-title":"Blood"},{"issue":"7","key":"2023080717055119300_bib12","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1182\/blood-2014-11-610436","article-title":"Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells","volume":"125","author":"Reichel","year":"2015","journal-title":"Blood"},{"issue":"3","key":"2023080717055119300_bib13","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1182\/blood.V98.3.762","article-title":"STAT3 is constitutively activated in Hodgkin cell lines","volume":"98","author":"Kube","year":"2001","journal-title":"Blood"},{"issue":"18","key":"2023080717055119300_bib14","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1038\/sj.onc.1209151","article-title":"Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation","volume":"25","author":"Weniger","year":"2006","journal-title":"Oncogene"},{"issue":"4","key":"2023080717055119300_bib15","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/ng.2900","article-title":"Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma","volume":"46","author":"Gunawardana","year":"2014","journal-title":"Nat Genet"},{"issue":"12","key":"2023080717055119300_bib16","first-page":"591","article-title":"Epstein-Barr virus and the origin of Hodgkin lymphoma","volume":"33","author":"Vockerodt","year":"2014","journal-title":"Chin J Cancer"},{"issue":"12","key":"2023080717055119300_bib17","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1084\/jem.189.12.1939","article-title":"Interleukin 13 is secreted by and stimulates the growth of Hodgkin and Reed-Sternberg cells","volume":"189","author":"Kapp","year":"1999","journal-title":"J\u00a0Exp Med"},{"issue":"8","key":"2023080717055119300_bib18","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1182\/blood-2008-01-134783","article-title":"Aberrant expression of the Th2 cytokine IL-21 in Hodgkin lymphoma cells regulates STAT3 signaling and attracts Treg cells via regulation of MIP-3alpha","volume":"112","author":"Lamprecht","year":"2008","journal-title":"Blood"},{"issue":"9","key":"2023080717055119300_bib19","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1182\/blood-2007-08-105643","article-title":"IL-21 is expressed in Hodgkin lymphoma and activates STAT5: evidence that activated STAT5 is required for Hodgkin lymphomagenesis","volume":"111","author":"Scheeren","year":"2008","journal-title":"Blood"},{"issue":"5","key":"2023080717055119300_bib20","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1002\/ijc.24389","article-title":"Functional coexpression of interleukin (IL)-7 and its receptor (IL-7R) on Hodgkin and Reed-Sternberg cells: involvement of IL-7 in tumor cell growth and microenvironmental interactions of Hodgkin's lymphoma","volume":"125","author":"Cattaruzza","year":"2009","journal-title":"Int J Cancer"},{"issue":"11","key":"2023080717055119300_bib21","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nrc2734","article-title":"STATs in cancer inflammation and immunity: a leading role for STAT3","volume":"9","author":"Yu","year":"2009","journal-title":"Nat Rev Cancer"},{"issue":"23","key":"2023080717055119300_bib22","doi-asserted-by":"crossref","first-page":"4609","DOI":"10.1182\/blood-2012-05-428896","article-title":"Analyzing primary Hodgkin and Reed-Sternberg cells to capture the molecular and cellular pathogenesis of classical Hodgkin lymphoma","volume":"120","author":"Tiacci","year":"2012","journal-title":"Blood"},{"issue":"23","key":"2023080717055119300_bib23","doi-asserted-by":"crossref","first-page":"4065","DOI":"10.1182\/bloodadvances.2019001012","article-title":"Genomic analyses of flow-sorted Hodgkin Reed-Sternberg cells reveal complementary mechanisms of immune evasion","volume":"3","author":"Wienand","year":"2019","journal-title":"Blood Adv"},{"issue":"12","key":"2023080717055119300_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/bcj.2011.46","article-title":"The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma","volume":"1","author":"Derenzini","year":"2011","journal-title":"Blood Cancer J"},{"issue":"4","key":"2023080717055119300_bib25","doi-asserted-by":"crossref","first-page":"e18856","DOI":"10.1371\/journal.pone.0018856","article-title":"Lestaurtinib inhibition of the JAK\/STAT signaling pathway in Hodgkin lymphoma inhibits proliferation and induces apoptosis","volume":"6","author":"Diaz","year":"2011","journal-title":"PLoS One"},{"issue":"3","key":"2023080717055119300_bib26","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1158\/0008-5472.CAN-10-2987","article-title":"Dynamic mathematical modeling of IL13-induced signaling in Hodgkin and primary mediastinal B-cell lymphoma allows prediction of therapeutic targets","volume":"71","author":"Raia","year":"2011","journal-title":"Cancer Res"},{"issue":"4","key":"2023080717055119300_bib27","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.cellsig.2005.05.010","article-title":"Constitutive activation of STAT proteins in the HDLM-2 and L540 Hodgkin lymphoma-derived cell lines supports cell survival","volume":"18","author":"Cochet","year":"2006","journal-title":"Cell Signal"},{"issue":"11","key":"2023080717055119300_bib28","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1158\/1078-0432.CCR-11-3145","article-title":"Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis","volume":"18","author":"Mascarenhas","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2023080717055119300_bib29","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1186\/s12885-019-6303-z","article-title":"Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma","volume":"19","author":"Kim","year":"2019","journal-title":"BMC Cancer"},{"issue":"29","key":"2023080717055119300_bib30","doi-asserted-by":"crossref","first-page":"20928","DOI":"10.18632\/oncotarget.25037","article-title":"Sequential immunotherapy in a patient with primary refractory Hodgkin lymphoma and novel mutations","volume":"9","author":"Greil","year":"2018","journal-title":"Oncotarget"},{"issue":"5","key":"2023080717055119300_bib31","doi-asserted-by":"crossref","first-page":"840","DOI":"10.3324\/haematol.2017.180554","article-title":"A\u00a0phase II study of the oral JAK1\/JAK2 inhibitor ruxolitinib in advanced relapsed\/refractory Hodgkin lymphoma","volume":"103","author":"Van Den Neste","year":"2018","journal-title":"Haematologica"},{"issue":"2","key":"2023080717055119300_bib32","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1182\/blood-2002-04-1128","article-title":"Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays","volume":"101","author":"Garcia","year":"2003","journal-title":"Blood"},{"issue":"pt 1","key":"2023080717055119300_bib33","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1042\/bj3570263","article-title":"Relationships between inhibition constants, inhibitor concentrations for 50% inhibition and types of inhibition: new ways of analysing data","volume":"357","author":"Cort\u00e9s","year":"2001","journal-title":"Biochem J"},{"issue":"43","key":"2023080717055119300_bib34","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"2023080717055119300_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pcbi.1004310","article-title":"Time-course gene set analysis for longitudinal gene expression data","volume":"11","author":"Hejblum","year":"2015","journal-title":"PLoS Comput Biol"},{"issue":"6","key":"2023080717055119300_bib36","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The Molecular Signatures Database (MSigDB) hallmark gene set collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst"},{"issue":"2","key":"2023080717055119300_bib37","doi-asserted-by":"crossref","first-page":"555","DOI":"10.3892\/ijo.2016.3827","article-title":"Activation of oncogenic pathways in classical Hodgkin lymphoma by decitabine: a rationale for combination with small molecular weight inhibitors","volume":"50","author":"Swerev","year":"2017","journal-title":"Int J Oncol"},{"issue":"11","key":"2023080717055119300_bib38","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1038\/leu.2014.201","article-title":"The mutational landscape of Hodgkin lymphoma cell lines determined by whole-exome sequencing","volume":"28","author":"Liu","year":"2014","journal-title":"Leukemia"},{"issue":"15","key":"2023080717055119300_bib39","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1182\/blood.2019004725","article-title":"Genome-wide transcriptome analysis of the STAT6-regulated genes in advanced-stage cutaneous T-cell lymphoma","volume":"136","author":"Gaydosik","year":"2020","journal-title":"Blood"},{"issue":"1","key":"2023080717055119300_bib40","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.exphem.2016.10.008","article-title":"Granulocyte colony-stimulating factor receptor signaling in severe congenital neutropenia, chronic neutrophilic leukemia, and related malignancies","volume":"46","author":"Dwivedi","year":"2017","journal-title":"Exp Hematol"},{"issue":"19","key":"2023080717055119300_bib41","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1214514","article-title":"Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML","volume":"368","author":"Maxson","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"2023080717055119300_bib42","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1046\/j.1365-2141.2002.03894.x","article-title":"An unbalanced translocation involving chromosome 14 is the probable cause for loss of potentially functional rearranged immunoglobulin heavy chain genes in the Epstein-Barr virus-positive Hodgkin's lymphoma-derived cell line L591","volume":"119","author":"Vockerodt","year":"2002","journal-title":"Br J Haematol"},{"issue":"10","key":"2023080717055119300_bib43","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1200\/JCO.2017.77.3994","article-title":"Major histocompatibility complex class II and programmed death ligand 1 expression predict outcome after programmed death 1 blockade in classic Hodgkin lymphoma","volume":"36","author":"Roemer","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"2023080717055119300_bib44","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1158\/2326-6066.CIR-16-0201","article-title":"Classical Hodgkin lymphoma with reduced \u03b22M\/MHC class I expression is associated with inferior outcome independent of 9p24.1 status","volume":"4","author":"Roemer","year":"2016","journal-title":"Cancer Immunol Res"},{"issue":"3","key":"2023080717055119300_bib45","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1159\/000095558","article-title":"Pathobiology of classical Hodgkin lymphoma","volume":"73","author":"Tzankov","year":"2006","journal-title":"Pathobiology"},{"issue":"3","key":"2023080717055119300_bib46","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0046-8177(93)90034-E","article-title":"Abundant expression of transforming growth factor-beta 1 and -beta 2 by Hodgkin's Reed-Sternberg cells and by reactive T lymphocytes in Hodgkin's disease","volume":"24","author":"Hsu","year":"1993","journal-title":"Hum Pathol"},{"issue":"1","key":"2023080717055119300_bib47","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1006\/cimm.2001.1828","article-title":"Suppression of an IL-13 autocrine growth loop in a human Hodgkin\/Reed-Sternberg tumor cell line by a novel IL-13 antagonist","volume":"211","author":"Oshima","year":"2001","journal-title":"Cell Immunol"},{"issue":"14","key":"2023080717055119300_bib48","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1080\/10428194.2019.1636983","article-title":"Classical Hodgkin lymphoma cells may promote an IL-17-enriched microenvironment","volume":"60","author":"Ferrarini","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2023080717055119300_bib49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2007.07.004","article-title":"The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages","volume":"66","author":"Allavena","year":"2008","journal-title":"Crit Rev Oncol Hematol"},{"issue":"11","key":"2023080717055119300_bib50","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nri3088","article-title":"Transcriptional regulation of macrophage polarization: enabling diversity with identity","volume":"11","author":"Lawrence","year":"2011","journal-title":"Nat Rev Immunol"},{"issue":"11","key":"2023080717055119300_bib51","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1016\/j.celrep.2015.08.033","article-title":"TNF counterbalances the emergence of M2 tumor macrophages","volume":"12","author":"Kratochvill","year":"2015","journal-title":"Cell Rep"},{"issue":"4","key":"2023080717055119300_bib52","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.4049\/jimmunol.1000475","article-title":"Dendritic cell-specific ICAM-3-grabbing nonintegrin expression on M2-polarized and tumor-associated macrophages is macrophage-CSF dependent and enhanced by tumor-derived IL-6 and IL-10","volume":"186","author":"Dom\u00ednguez-Soto","year":"2011","journal-title":"J\u00a0Immunol"},{"issue":"8","key":"2023080717055119300_bib53","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1038\/sj.bjc.6605238","article-title":"Inflammation and tissue repair markers distinguish the nodular sclerosis and mixed cellularity subtypes of classical Hodgkin's lymphoma","volume":"101","author":"Birgersdotter","year":"2009","journal-title":"Br J Cancer"},{"issue":"6","key":"2023080717055119300_bib54","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1073\/pnas.1524668113","article-title":"Augmented efficacy of brentuximab vedotin combined with ruxolitinib and\/or Navitoclax in a murine model of human Hodgkin's lymphoma","volume":"113","author":"Ju","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"2023080717055119300_bib55","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/ijc.28189","article-title":"Targeting the IL-4\/IL-13 signaling pathway sensitizes Hodgkin lymphoma cells to chemotherapeutic drugs","volume":"133","author":"Natoli","year":"2013","journal-title":"Int J Cancer"},{"issue":"3","key":"2023080717055119300_bib56","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.cyto.2008.03.002","article-title":"Granulocyte colony-stimulating factor: molecular mechanisms of action during steady state and 'emergency' hematopoiesis","volume":"42","author":"Panopoulos","year":"2008","journal-title":"Cytokine"},{"issue":"1","key":"2023080717055119300_bib57","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12943-018-0774-4","article-title":"Targeting few to help hundreds: JAK, MAPK and ROCK pathways as druggable targets in atypical chronic myeloid leukemia","volume":"17","author":"Rocca","year":"2018","journal-title":"Mol Cancer"},{"issue":"24","key":"2023080717055119300_bib58","doi-asserted-by":"crossref","first-page":"13670","DOI":"10.1073\/pnas.1918307117","article-title":"Combined inhibition of JAK\/STAT pathway and lysine-specific demethylase 1 as a therapeutic strategy in CSF3R\/CEBPA mutant acute myeloid leukemia","volume":"117","author":"Braun","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"20","key":"2023080717055119300_bib59","doi-asserted-by":"crossref","first-page":"5269","DOI":"10.1182\/bloodadvances.2020002013","article-title":"Heterozygous germ line CSF3R variants as risk alleles for development of hematologic malignancies","volume":"4","author":"Trottier","year":"2020","journal-title":"Blood Adv"},{"issue":"6","key":"2023080717055119300_bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0125203","article-title":"CSF1R protein expression in reactive lymphoid tissues and lymphoma: its relevance in classical Hodgkin lymphoma","volume":"10","author":"Martin-Moreno","year":"2015","journal-title":"PLoS One"},{"issue":"24","key":"2023080717055119300_bib61","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1182\/blood-2016-03-705053","article-title":"Chemo-genomic interrogation of CEBPA mutated AML reveals recurrent CSF3R mutations and subgroup sensitivity to JAK inhibitors","volume":"127","author":"Lavall\u00e9e","year":"2016","journal-title":"Blood"},{"issue":"5","key":"2023080717055119300_bib62","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/gcc.22345","article-title":"Genomic alterations of the JAK2 and PDL loci occur in a broad spectrum of lymphoid malignancies","volume":"55","author":"Van Roosbroeck","year":"2016","journal-title":"Genes Chromosomes Cancer"},{"issue":"2","key":"2023080717055119300_bib63","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1182\/blood.V99.2.618","article-title":"Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma","volume":"99","author":"Skinnider","year":"2002","journal-title":"Blood"},{"issue":"5","key":"2023080717055119300_bib64","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/s41379-019-0428-0","article-title":"Diagnostic utility of STAT6","volume":"33","author":"Van Slambrouck","year":"2020","journal-title":"Mod Pathol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/15\/4135\/2069811\/blooda_adv-2021-006336r3-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/15\/4135\/2069811\/blooda_adv-2021-006336r3-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T13:06:49Z","timestamp":1691413609000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/15\/4135\/493385\/JAK-STAT-blockade-reverses-the-malignant-phenotype"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,1]]},"references-count":64,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2023,8,8]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021006336","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,1]]}}}